Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A new class action lawsuit against ADMA Biologics (ADMA) alleges securities fraud violations and urges investors to seek recovery, with a lead plaintiff deadline of 8/10/2026. While details of damages are not provided, the filing adds legal/regulatory overhang that could weigh on sentiment and increase potential cost/liability risk for the company.

Analysis

A new class action lawsuit against ADMA Biologics (ADMA) alleges securities fraud violations and urges investors to seek recovery, with a lead plaintiff deadline of 8/10/2026. While details of damages are not provided, the filing adds legal/regulatory overhang that could weigh on sentiment and increase potential cost/liability risk for the company.